Plate Nº 10 · recorded October 10, 2026
Health & Medicine ResearchReported finding
Master Protocol Trials Could Reshape Rare Disease Research
Researchers propose master protocol trials to test multiple rare disease therapies at once, cutting costs and speeding treatments for conditions that today affect one in 10 people.
By Priya Raman3 min read662 words
In brief
- The FDA approved 45 drug therapies for neurological conditions in the past decade, covering only 26 conditions — about 4% of diagnosed neurological disorders.
- One in 10 people is diagnosed with a rare disease; more than 10,000 rare diseases exist, most with neurological symptoms.
- The study by Jennifer Vermilion et al. appears in Annals of Neurology (2026), DOI: 10.1002/ana.78311.
- Seven institutions collaborated on the publication, led by Kennedy Krieger Institute and University of Rochester Medicine.
- The U.S. defines a rare disease as a condition affecting fewer than 200,000 people.
Only 26 conditions — roughly 4% of all diagnosed neurological disorders — have approved drug therapies, despite the U.S. Food and Drug Administration clearing 45 treatments for neurological conditions over the past decade. Researchers from Kennedy Krieger Institute, University of Rochester Medicine and five other institutions now argue there is a faster path forward: master protocol trials.
The team laid out its case in a new publication in the journal Annals of Neurology (DOI: 10.1002/ana.78311, 2026). Their central claim is simple. By testing multiple drugs or conditions within a single shared clinical framework, researchers could cut costs, improve testing efficiency and capacity, and deliver treatments to rare disease patients sooner.
What is a master protocol trial?
A traditional clinical trial builds a new framework for every new drug or condition under investigation. That means separate recruitment, separate paperwork, separate infrastructure — a costly repetition when patient populations are small.
A master protocol works differently. Researchers test multiple drugs or multiple conditions at the same time using one common clinical framework. For rare diseases, where each condition may affect only a handful of patients, sharing that infrastructure could make trials feasible where they otherwise would not be.
Why do rare diseases need a new approach?
The United States defines a rare disease as a condition affecting fewer than 200,000 people. Yet rarity is collectively common: one in 10 people receives a rare disease diagnosis in their lifetime. More than 10,000 rare diseases exist, and most involve neurological symptoms, ranging from problems with body control to developmental disabilities.
For most of these patients, no treatment exists at all.
The researchers say biology is now on their side. Rare disease scientists recently discovered that similar genetic markers appear across multiple conditions. Combined with the development of targeted gene therapies, that shared biology could allow master protocol trials to test treatments across several rare diseases carrying similar genetic mutations at once.
What did the researchers say?
"Families living with rare neurological diseases cannot afford to wait for scientific progress to move at a traditional pace," said Dr. Erika Augustine, associate chief science officer and director of the Clinical Trials Unit at Kennedy Krieger Institute and the study's senior author. "Master protocol trials offer a smarter, more collaborative way to evaluate potential therapies and bring effective treatments to patients more efficiently."
Dr. Jennifer Vermilion, director of the University of Rochester Batten Center of Excellence and the study's lead author, emphasized that the paper itself models the approach it proposes.
"The collaboration behind this paper reflects the same principle we hope to advance through master protocols," Vermilion said. "Working together, rather than in isolation, can help us answer important questions more efficiently and accelerate progress for patients and families."
Who contributed to the study?
The publication resulted from a collaborative effort spanning seven institutions and organizations:
- University of Rochester Medicine
- Mass General Brigham, Spaulding Rehabilitation and Harvard Medical School
- Berry Consultants
- The Clinical Trials Transformation Initiative at Duke University
- The Batten Disease Support, Research, and Advocacy Foundation
- Rady Children's Health and UC Irvine
- Kennedy Krieger Institute
The full study, "The Case for Master Protocols for Rare Neurological Diseases" by Jennifer Vermilion et al., appears in Annals of Neurology (2026).
What are the caveats?
The publication is a position paper making a scientific and practical case, not a report of results from completed master protocol trials in rare neurological disease. Whether the approach delivers on its promise of lower costs and faster treatments will depend on how future trials perform in practice — and on regulators, funders and institutions adopting the shared frameworks the authors describe.
Still, the underlying math is hard to ignore. With 45 FDA-approved drug therapies for neurological conditions in a decade covering just 4% of diagnosed neurological disorders, the traditional one-trial-at-a-time model is not closing the gap. The authors argue that testing smarter, together, may be the only realistic way to reach the other 96%.
via Medical Xpress (Source)
More from Priya Raman
Show full bio
Senior reporter covering industry trends and analytics at SciBeat.
207 articles
Nearby plates
- Cambridge reports first-in-human cell therapy results for Parkinson's
- Alzheimer's Drug Matches Trial Results in Real-World Patients
- Study Cited by Axios Suggests AI Brings Savings to Clinical Trials
- Short-Acting Psychedelic Tested Against Major Depression in Phase IIa Trial
- Alzheimer's Drug Developers Accuse Trial Sites of Faking Data